CD8A and hepatocellular carcinoma: Expanding on bacterial precision, PD-1@EcM employs nonpathogenic E. coli with acid-responsive gene circuits to produce anti-PD-1 scFv in residual tumors post-thermal ablation, repolarizing TAMs and priming CD8+ T cells in HCC models [125].